Codexis Licenses Enzymes To GSK | Chemical & Engineering News
Volume 92 Issue 29 | p. 16 | Concentrates
Issue Date: July 21, 2014

Codexis Licenses Enzymes To GSK

Department: Business
Keywords: pharmacueticals, enzymes, biocatalysis, manufacturing

Biocatalyst developer Codexis has licensed its enzyme engineering technology to GlaxoSmithKline for making pharmaceuticals and other health care products. GSK will pay Codexis $6 million up front and another $19 million over two years as it transfers the technology to its Upper Merion, Pa., R&D site. Under the license, GSK can use the technology to develop enzymes for manufacturing processes and to create therapeutic, diagnostic, and prophylactic products. Codexis could receive milestone payments of up to $39 million per project, plus royalties, if GSK is successful in using the technology.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment